AUTHOR INDEX

Volume 30, 1994

Abe, M., 979, 1099, 1147, 1153
Abner, A., 17
Akanuma, A., 1059, 1171, 1233
Alatriste, S., 799
Aletti, P., 1051
Alexander, III, E., 531, 731
Allavena, C., 1051
Altendorf-Hofmann, A., 261
Amalric, R., 3
Amdur, R. J., 83
Ammarguellat, H., 821
Anderson, Jr., R. F., 825
Ando, K., 867
Ang, K. K., 347, 619, 795
Anscher, M. S., 671
Antunovic, V., 1179
Aoki, S., 1201
Aoki, Y., 1059, 1171, 1233
Aragón, G., 1091
Arasaki, A., 1219
Arisz, L., 677
Armstrong, J. G., 953
Aronen, H. J., 663
Arora, V. R., 693
Asbell, S. O., 289
Ashley, S., 781, 805
Asselain, B., 35
Austin-Seymour, M., 1065
Avilés, A., 799

Bacher, J. D., 339
Bagshaw, M. A., 504
Bahk, Y.-W., 873
Baker, F., 789
Baker, S., 887
Banfi, A., 813
Bannon, J., 845
Barendsen, G. W., 447
Barnes, P. D., 531
Barrett, W., 3
Bartelink, H., 1017, 1073; 30(5), xxxix
Bastin, K., 541
Batata, M., 831
Baudet, J.-J., 1133
Beckman, W. A., 929
Bedford, J. S., 83
Bellerive, M., 685
Belloc, F., 1133
Bentel, G. C., 508, 671
Berger, M. S., 567
Bernheim, A., 789
Bernstein, M., 1213
Beuerlein, G., 715
Bey, P., 1051
Biaglow, J. E., 879
Bishop, K., 839
Black, P. McL., 531
Boerner, P., 715
Bonfante, V., 813
Boothman, D. A., 391
Borger, J. H., 1073
Bortfeld, T., 899
Bosch, W. R., 431
Boström, P., 177
Bova, F. J., 755, 765, 775
Boyer, A. L., 899
Boyle, B. J., 309
Brady, L. W., 245
Brenner, D. J., 241, 501, 721
Brewster, L. J., 971
Bridier, A., 821
Brierley, J. D., 557
Briot, E., 821
Brizel, D. M., 635
Brock, W. A., 363
Brodovsky, H., 169
Brown, J. M., 355, 1127
Brundage, M., 221
Buchler, D. A., 75
Burgess, A. C., 861
Burman, C., 971
Burnet, N. G., 625
Busch, D., 997
Bussières, E., 1083
Button, T. M., 643
Byers, R. M., 795

Cajigal, C., 1091
Campana, F., 35
Caplan, R., 1065
Caputo, T., 831
Cárdenes, H., 1091
Carlsson, J., 105
Carper, E., 953
Carroll, P., 323
Cassady, J. R., 591, 945
Castellani, M. R., 813
Centeno, B. A., 309
Cetas, T. C., 653, 945
Chadha, M., 55
Chan, D. K. K., 1111
Chaney, E. L., 439
Chappell, R., 75, 541, 1111
Chauvergne, J., 1083
Chemin, A., 1083
Chen, E.-T., 169
Chen, J., 921
Cheng, A., 431
Cheng, C. W., 183
Cheung, F. K., 1111
Chon, Y., 609
Choy, D., 1029
Chui, C. S., 971
Clark, J., 1043
Clark, R., 11
Coachman, N., 1043
Cobleigh, M. A., 49
Coderre, J. A., 643
Coggins, J., 921
Coia, L., 161
Coleman, C. N., 879, 1247
Coleman, L., 323
Colvin, R. B., 309
Connolly, J. L., 17
Cook, J. A., 583, 879
Cosset, J.-M., 477, 789, 821
Cousins, S., 921
Cowen, D., 1133
Cox, R. S., 504
Cragoe, Jr., E. J., 133, 1161
Crook, J., 303
Cullip, T. J., 439

D'Amico, A. V., 293
Das, I. J., 183
Davis, T. W., 391
de la Rochefordiere, A., 35
de la Torre, A., 1091
Debus, J., 521
Delgado, S., 799
DeLuca, A. M., 339
Denardo, G. L., 737
Denardo, S. J., 737
DeNittis, A., 175
DeRosa, E., 1043
Devizzi, L., 813
Dewhirst, M. W., 635
Dewit, G. H., 677
Diaz, A., 323
Diaz, A. Z., 501
Díaz-Maqueo, J. C., 799
Dixon, P., 221
Djuric, L., 1179
Domenico, D., 839
Doolittle, III, C., 1043
Dräger, A., 117
Drzymala, R., 921
Drzymala, R. E., 459, 909
Du, M. N., 707
Dubray, B., 477
Duggal, N., 625
Dunbar, S. F., 531, 685
Dunst, J., 261
Durand, J.-C., 35
Duverger, A., 789
Duvillard, P., 789

Edwards, M. S. B., 551
Eggleston, W., 839
Eisenberg, B., 161
Eiter, H., 419
Emami, B., 887, 909
Encinas, J. L., 1091
Engenhart, R., 521
Ennis, R. D., 317
Enpi, Z., 1037
Epp, E. R., 495
Epstein, A. H., 583
Esche, B., 303
Essand, M., 105
Evans, J. W., 1127
Ezzell, G., 473

Fang, Q., 1037
Fass, D., 211
Feng, Z., 1037
Ferarro, N., 685
Fertil, B., 789
Fiedler, J. A., 985
Finn, L., 685
Fischer, D. B., 317
Fischman, A. J., 663
Fishbein, G., 169
Fisher, C. D., 643
Fitzgerald, C. R., 755, 765, 775
Flynn, S. D., 317
Fontenla, D. P., 211
Foo, W., 1111
Forman, J. D., 427
Forman, S. J., 965
Foster, G., 11
Fourquet, A., 3, 35, 477
Fowble, B., 237
Fowble, B. L., 3, 23
Fowler, J. F., 75, 1111
Fox, K., 23
Frankenthaler, R. A., 795
Frikha, H., 1207
Fu, H., 221
Fujii, H., 1201
Fuks, Z., 91, 229, 405, 971
Furukawa, S., 867

Gabel, M., 99
Gannett, D. E., 567
Garden, A. S., 795
Gaynor, J. J., 953
Geara, F. B., 331
Gedda, L., 105
Geering, L., 427
Gerber, R., 431, 887
Girinsky, T., 477, 789, 821
Glatstein, E., 583
Glen, J., 1213
Glick, J. H., 23
Glicksman, A. S., 1043
Gluckman, E., 477, 821
Goepfert, H., 795
Goetsch, S. J., 745
Goffman, T. E., 583
Goldmann, A. R., 63
Gonzalez, F. J., 879
Gospodarowicz, M. K., 557
Goswami, G., 985
Goumnerova, L., 531
Graham, M. L., 887
Graham, M. V., 431
Grau, C., 1141
Gray, K. N., 347
Grdina, D. J., 867

Greenberg, H. S., 601
Greer, B. E., 411
Grégoire, V., 363
Gregoritch, S. J., 55
Griem, K. L., 49
Griffin, R. J., 133, 1161
Griffin, T. W., 411
Griffin, T., 1065
Grigsby, P. W., 887
Grönvik, C., 105
Grujicic, D., 1179
Gualde, N., 1133
Guo, K.-P., 1107
Gustafson, G., 707

Ha, C. S., 795
Haddad, E., 1207
Haffty, B., 3
Hahn, G. M., 141
Hall, E. J., 241, 501, 1019
Hallahan, D., 229
Halpern, H., 151
Hamilton, A., 591
Hanakawa, K., 1233
Hanks, G., 161
Hanks, G. E., 43, 289
Hanson, W. F., 455
Hara, R., 1219
Harms, W., 887, 921
Harms, W. B., 909
Harrelson, J., 635
Harris, J. R., 17
Harrison, L., 405
Harrison, L. B., 953
Harsh, G. R., 663
Hart, A., 1073
Hartman, T., 75, 105
Hartsell, W. F., 49
Hasezawa, K., 1059, 1171
Hazle, J. D., 455
He, T., 427
Heimann, R., 151
Heller, D. P., 383
Hergan, K., 419
Herscher, L. L., 583, 879
Hill, R. P., 125
Hiraoka, M., 979, 1099
Hittelman, W. N., 363
Ho, J. H. C., 1111
Hochberg, F. H., 663
Hoffman, J., 43, 161
Hoffman, L. G., 825
Hoffstetter, S., 1051
Holland, K. W., 993
Holman, M. D., 909
Hopewell, J. W., 506, 1119
Horrobin, D. F., 1119
Horwich, A., 805
Hoskin, P. J., 502
Houdek, P. V., 985
Höver, K.-H., 521
Høyer, M., 1141
Hu, Z.-X., 1107
Huang, Y.-W., 1107
Huaqing, M., 1037
Huijgens, P. C., 117, 447
Hummel, S., 1065
Hunt, M., 211
Hunter, N., 363
Hunter, N. R., 619

Ide, H., 959
Indik, J. H., 653
Indik, R. A., 653
Investigators of the Ontario Clinical Oncology Group, 11
Irving, D., 839

Jacky, J., 921, 1065
Jain, N. L., 909
Jang, H.-S., 873
Jannoun, L., 781
Janot, F., 789
Jardines, L., 23
Jeremic, B., 1179
Jin, Z., 1037
Jinming, Z., 1037
Jirtle, R. L., 671
Joensuu, H., 177, 1195
Johnson, E., 715
Johnston, P. G., 851
Johnstone, P. A. S., 339
Jonkhoff, A. R., 117
Jun, M., 1037

Kahler, D. L., 899
Kahn, M., 921
Kahn, M. G., 909
Kakihana, Y., 1219
Kalet, I., 921
Kaneyasu, Y., 959
Kantorowitz, D. A., 55
Kao, G., 293
Kaplan, I. D., 504
Karasawa, K., 959, 1059, 1171
Karim, A. B. M. F., 727
Kavadi, V. S., 279
Kavanagh, B. D., 508
Kawakami, H., 1233
Keilholz, L., 63
Kemperman, H., 1073
Kennedy, D., 663
Khil, M. S., 99
Kim, G. E., 1161
Kim, J. H., 99
Kim, S.-H., 99
Kimmig, B. N., 521
King, S. C., 693
Kinsella, T., 541
Kinsella, T. J., 75, 339, 583, 851
Kita, M., 959
Kittelson, J., 591, 945
Klein, E. E., 459
Klein, S. A., 929
Koh, W.-J., 411
Koike, S., 867
Koja, S., 1219
Koness, J., 1043
Konski, A., 839
Kooy, H. M., 531, 685
Kosuda, S., 1201
Kotoura, Y., 1147
Kovacs, M. S., 1127
Kozar, M., 289
Kozminski, P., 1051
Krishna, M. C., 879
Kromhout-Schiro, S., 921
Kubsad, S., 541
Kufe, D., 229
Kühn, R., 261
Kunugi, K. A., 851
Kurtz, H., 411
Kurtz, J., 3
Kushi, A., 1219
Kuske, R., 3
Kutcher, G. J., 211, 971
Kwong, D., 1029

La Vally, B., 531
Lagarde, P., 1133
Lanciano, R., 43
Landon, A. E., 1213
Landriau, S., 1133
Lane, R. G., 699
Lang, P., 715
Langer, M. L., 699
Lapela, M., 1195
Laperriere, N., 1213
Laperriere, N. J., 575
Laramore, G., 1065
Larson, D. A., 541
Lavey, R. S., 609
Law, S. C. K., 1111
Lawrence, T. S., 601, 861
Le Bourgeois, J. P., 1207
Le, Q.-T. X., 551
Leavitt, D. D., 205
Lebesque, J., 1073
Lee, A. W. M., 1111
Lee, C. K. K., 1003
Lee, H. K., 887
Lee, K. C., 504
Lee, Y. J., 99
Lehrer, S., 509
Leibel, S. A., 971
Leigh, B. R., 945
Leopold, K. A., 693
Leskinen-Kallio, S., 1195
Leung, P., 1213
Levin, A., 541
Levin, V. A., 551
Levine, M., 11
Levitt, S. H., 1003
Levy, E., 1207
Li, L. T., 609
Light, K. L., 693
Lindholm, P., 1195
Lindsley, K., 1065
Lindstrom, M. J., 851
Lindström, P., 105
Ling, C. C., 971
Linggood, R. M., 663
Lipsett, J. A., 965
Liu, H. B., 643
Loeffler, J. S., 497, 531, 685, 731, φφφ
Lorenz, W., 521
Lövqvist, A., 105
Lubin, R., 789
Lundqvist, H., 105
Luo, R.-X., 1107
Luporsi, E., 1051
Lustig, R. A., 715
Lyons, J. C., 133, 1161
Macbeth, F., 508
Machtay, M., 43
Mackie, T., 541
Mackillop, W. J., 221
Magallón, R., 1091
Mageras, G. S., 971
Mah, J., 839
Mahon, F.-X., 1133
Makepeace, C. M., 133, 1161
Makkonen, T. A., 177
Malissard, L., 1051
Malkowicz, S. B., 293
Malmqvist, J., 105
Mancini, W. R., 601
Mannarino, E., 685
Mansfield, C. M., 503
Marks, G., 169, 845
Marks, L. B., 243, 671
Marquez, C., 323
Martin, L., 1207
Martinez, A., 707
Martus, P., 63
Maruyama, Y., 473
Masciopinto, J., 541
Masterson, M. E., 971
Matsumoto, H., 1225
Matsushita, S., 867
Matter, R. C., 707
Matthews, J., 887
Matthews, R. H., 509
Maxy, R., 91
McBride, W. H., 609
McCormick, B., 3, 197, 211
McDonough, C. V., 685
McGinn, C. J., 851
McLaughlin, P. W., 601
McNeese, M., 3
Mehta, M. P., 541, 746
Meigooni, A. S., 399
Mendenhall, W. M., 755, 765, 775
Merchant, T. E., 197
Merimsky, O., 831
Merriam, Jr., G. R., 721
Mesina, C. F., 427
Metz, J., 715
Meyn, R. E., 619
Micca, P. L., 643
Michalski, J., 501
Michalski, J. M., 431, 887
Milas, L., 363, 619
Miles, J., 541
Miller, E. M., 851
Million, R. R., 755, 765, 775
Milosevic, M., 575
Minghuang, H., 1037
Mitchell, J. B., 583, 879
Mitsuhashi, N., 247, 1225
Mitsumori, M., 979
Mivechi, N. F., 141
Mizowaki, T., 979
Moeller, J. H., 205
Mohan, R., 971
Mohiuddin, M., 169, 845
Monson, J. M., 141
Montana, G. S., 508
Moros, E. G., 399
Morrill, S. M., 699

Morris, G. M., 1119
Morrison, W. H., 795
Morrow, M., 235
Moulton, G., 663
Mundt, A. J., 151
Murase, T., 671
Murata, R., 979
Murata, Y., 959
Murthy, A. K., 49
Muta, N., 1059, 1171, 1233
Myerson, R. J., 399

Nagata, Y., 979
Nakagawa, K. 1059, 1171, 1233
Nakamura, O., 1201
Nakano, M., 1219
Nambo, M. J., 799
Napoli, J. J., 211
Narayan, P., 323
Nawrocky, M. M., 643
Negretti, E., 813
Neisler, J., 839
Neuberg, D., 17
Newcomb, C. H., 125
Nguyen, A. A., 609
Nguyen, N., 601
Niibe, H., 1225
Nishidai, T., 979
Nishimatsu, H., 1147
Nishimura, Y., 979, 1099
Nixon, A. J., 17
Nordman, E., 1195
Nori, D., 831
Normolle, D. P., 861

O'Brien, J., 971
O, S. K., 1111
Ogawa, K., 1219
Okajima, K., 979, 1099
Okawa, T., 959, 1017
Okunieff, P., 663
Oldfield, E. H., 583
Ollayos, C. W., 339
Olsson, P., 105
Ono, K., 979, 1099
Onogi, Y., 1059, 1171, 1233
Order, S. E., 715, 745
Orel, S., 23
Ornitz, R. D., 825
Ouyang, H., 141
Overgaard, J., 1017, 1141
Overmoyer, B., 23
Oya, N., 1099, 1153

Paiva, K., 663
Pajak, T. F., 289
Paliwal, B. R., 929
Panzarella, T., 557
Pardo, F. S., 663
Park, J.-M., 873
Parson, J. T., 755
Parsons, J. T., 765, 775
Patchell, R. A., 1253
Paul, A., 161
Peacock, J. H., 625
Peiffert, D., 1051
Pellegrini, Jr., V. D., 743
Pellegrini, V. D., 55
Perez, C. A., 289, 431, 887
Pernot, M., 1051
Peschel, R. E., 317, 493
Petereit, D. G., 75
Peters, L. J., 347, 795
Pezner, R. D., 965, 1251
Phibbs, G., 839
Pickett, B., 323
Piedbois, P., 1207
Pigneux, J., 1083
Pilchik, N. B., 715
Pilepich, M. V., 289
Pinot, J., 91
Plunkett, W., 363
Pollack, A., 267, 279, 331
Pomeroy, S. L., 531
Pontén, J., 105
Poon, Y. F., 1111
Porter, A. T., 473
Posner, M., 1043
Pouillart, P., 35
Prados, M. D., 551
Preffer, F. I., 309
Prescott, D. M., 671
Prezioso, J. A., 373
Price Mendenhall, N., 993
Principato, R., 715
Prosnitz, L. R., 243, 635
Purdy, J. A., 431, 459, 887, 909

Qixiang, Z., 1037
Quirt, C. F., 221

Raaphorst, G. P., 383
Rao, G. H., 1161
Ray, S. K., 693
Recht, A., 3, 17, 504
Recine, D. C., 49
Regueiro, C., 1091
Reiffers, J., 1133
Reisenbichler, H., 671
Rezvani, M., 1119
Rhomberg, W., 419
Rich, K. M., 459
Richaud, P., 1133
Rilke, F., 813
Rissman, S., 427
Roach, III, M., 323, 501, 510
Robbins, M. E. C., 347, 1119
Roberts, R., 11
Robertson, S., 303
Roos, J. C., 447
Rosen, B. R., 663
Rosen, I. I., 699
Rosenman, J. G., 439
Rosenstein, M., 373
Rosner, G. L., 635
Ross, G. A., 1119
Rossman, K., 591
Roy, J., 405
Rozental, J., 541
Rubin, P., 1, 55, 259, 519, 753, 1017; 30(5), xxxix
Rubin, S. J., 151
Russell, K., 1065
Ryu, S., 99

Sahijdak, W. M., 391
Sailer, S. L., 439
Saito, Y., 1225
Sakata, K., 1059, 1171, 1233
Sallan, S. E., 531
Santoro, A., 813
Sarkaria, J. N., 75
Sasai, K., 355, 1127, 1153
Sasaki, Y., 1059, 1171, 1233
Sauer, R., 63, 261
Scarantino, C. W., 825
Scher, R., 161
Schlegel, W., 899
Schmidt, E. V., 663
Schnall, M., 293
Schneider, B., 419
Schnitt, S., 17
Scholl, S., 35
Schrott, K. M., 261
Schultheiss, T. E., 735
Schultz, D., 293
Schultz, D. J., 3, 23
Scott, C. A., 1119
Scott, R. M., 531
Seabury, H., 601
Seegenschmiedt, M. H., 63
Serafini, A. N., 1187
Sessions, R. B., 953
Sham, J., 1029
Sharma, R., 427
Sherouse, G., 671, 921
Shetter, A., 591
Shibamoto, Y., 1147, 1153, 1179
Shibata, T., 1153
Shields, D., 373
Shinn, K.-S., 873
Shiojima, K., 1225
Shipley, J. W., 309
Shipley, W. U., 309, 743
Shitara, N., 1201
Shrieve, D. C., 497, 731, 1254
Shusterman, S., 685
Sibley, G. S., 151
Siegel, J. A., 715
Silbergeld, D. L., 567
Simpson, J. R., 459
Simpson. W. J., 557
Sindelar, W. F., 339
Sjöberg, S., 105
Slotman, G., 1043
Smith, J., 583
Smith, K. D., 693
Smitt, H. S., 1073
Sneed, P. K., 551
Sobczak, M. L., 309
Socie, G., 477, 821
Solin, L., 161
Solin, L. J., 3, 23
Sombeck, M. D., 993
Soncini, F., 813
Song, C. W., 133, 1161
Song, H. K., 509
Sontag, M. R., 693
Specht, L., 805
Spencer, D., 671
Stea, B., 183, 591, 945
Steeves, R. A., 929
Steinberg, S. M., 583
Stelzer, K. J., 411
Stephens, L. C., 347, 619
Stetson, P. L., 601
Stevenson, M. A., 1247
Stitt, J. A., 75
Stöckle, E., 1083
Stojanovic, M., 1179
Straube, W. L., 399
Sueyama, H., 1219
Sugimoto, M., 1147
Sugiyama, T., 1153
Suit, H. D., 495
Sullivan, F. J., 583
Sunakawa, H., 1219
Sutcliffe, S. B., 557
Suzuki, K., 1201
Swalec, J. J., 205
Swanson, D. A., 267
Symon, J. R., 439
Symons, M., 707
Syndikus, I., 781

Tait, D., 781
Takahashi, M., 979, 1225
Takahashi, S., 1147
Takizawa, Y., 1219
Tanaka, M., 959
Tanaka, Y., 1201
Tang, Q.-X., 1107
Tarbell, N. J., 531, 685
Tavakoli-Razavi, T., 789
Taylor, J. M. G., 609
Taylor, M., 3
Taylor, R., 707
Terahara, A., 1059, 1171, 1233
Terrill, R. E., 339
Teule, G. J. J., 117, 447
Thames, H. D., 347
Thomadsen, B. R., 75
Thomas, L., 1083
Thomason, C., 1213
Ting, J. Y., 985
Toita, T., 1219
Tomaszewski, J., 293
Tompkins, D. T., 929
Toulouse, C., 1083
Tracton, G., 921
Trent, J. M., 861
Tsang, R. W., 557
Tsutsui, K., 979, 1099
Tung, S. Y., 1111
Turski, P., 541
Tuttle, S. W., 879
Tward, J. D., 609
Tyrkus, M., 839

Ucla, L., 35
Unger, J., 921

v Dieren, E. B., 117
v.d. Loosdrecht, A. A., 117
Valcárcel, F., 1091
Valdés Olmos, R. A., 677
Valicenti, R., 501
Valicenti, R. K., 431
Valverde, S., 1091
van den Aardweg, G. J. M. J., 506, 1119

van den Berg, A. P., 506
van der Giessen, P.-T., 1239
van Dieren, E. B., 447
van Dongen, J., 1073
Van Dyk, J., 125, 575
van Lingen, A., 447
VanArsdalen, K., 293
Vanderby, R., 929
Verheij, M., 677
Versteegh, R. T., 117
Vilcoq, J. R., 35
Vilja, P., 177
Villani, F., 813
Viviani, S., 813
Vora, N., 965

Waldron, T. J., 899
Wallner, K., 405
Wallner, P. E., 715
Wanebo, H., 1043
Wang, N., 373
Wannenmacher, M., 521
Wara, W. M., 551
Wasserman, T. H., 459
Weber, R. S., 795
Weeks, K. J., 693
Weese, J., 161
Weichselbaum, R. R., 151, R. R., 229
Weil, M. D., 551
Wein, A., 293
Weiner, L., 161
Weinhous, M., 921
Westermark, B., 105
Whelan, T., 11
Whitehouse, E. M., 1119
Whittington, R., 293
Wibault, P., 789
Wilder, R. B., 737
Williams, S., 151
Williamson, J. F., 399
Wilt, S. R., 861
Wisbeck, W., 567
Witt, T. R., 49
Wittekind, C., 261
Wolfe, J. S., 323
Wölfel, R., 63
Wollman, R., 91
Wong, C. S., 575
Wong, J. W., 707
Wootton, P., 1065
Wowra, B., 521
Wurm, R., 625

Yaes, R. J., 505
Yahalom, J., 91
Yamada, A., 959
Yamakawa, M., 1225
Yamamuro, T., 1147
Yan, D., 707, 909, 921
Yankelevich, R., 985
Yarnold, J. R., 625
Yong, S., 1037
Yoon, S.-C., 873
Yu, C. X., 707

Zagars, G. K., 267, 279, 331
Zanini, M., 813, 1007
Zeiger, L. S., 715
Zelefsky, M., 405
Zelefsky, M. J., 953
Zhang, H., 715
Zhou, Y., 221
Zietman, A. L., 309, 741
Zucali, R., 813

SUBJECT INDEX

Volume 30, 1994

A

Accelerated hyperfractionation, 1099
Accelerated repopulation, 1099
Acquired immunodeficiency syndrome, 1207
Acute myeloblastic leukemia, 1133
Adenocarcinomas, 105
Advanced head and neck cancer, 1043
Advanced rectal cancer, 169
Adverse effects of radiotherapy, 755, 765, 775
Aerobic cytotoxicity, 879
Amiloride, 1161
Aminoalkycarborane, 105
Anti-microtubule agents, 99
Antineoplastic drugs, 997
Apoptosis, 619
Arteriovenous malformation, 521
Ataxia telangiectasia, 997
Auger electrons, 117
Autologous bone marrow transplantation, 151

B

Base of tongue cancer, 953
BCNT, 105
Beam modifiers, 211
Benign diseases, 63
Bioheat equation, 653
Bladder, 339
Bladder cancer, 261, 267
Bladder preservation, 261
Bone, 1147
Bone marrow transplant, 1133
Bone marrow transplantation, 477
Bone pain, 1187
Bone tumor, 1147
Boost field, 43
Boron, 105
Boron neuron capture therapy, 105
Boronophenylalanine, 643
Brachytherapy, 75, 405, 831, 1213
Brain neoplasm, 567
Brain tumor, 781
Brain tumors, 531
Breast, 183, 197
Breast cancer, 11, 49, 91, 197, 1073
Breast carcinoma, 35
Breast conservation therapy, 1073
Breast-conservation treatment, 3
Breast-conserving treatment, 35
Breast irradiation, 197
Breast neoplasms, 17
Breast radiotherapy, 43
Breast treatment, 205
Bromodeoxyuridine, 601, 861
BSO, 373
Build-up dose, 211
Bulky disease, 799

C

Caffeine, 411
Captopril, 873
Captopril renography, 677
Carboranyl amino acids, 105
Carcinoma, 405
Cell characterization, 789
Cell-cycle, 117
Cell growth fraction, 789
Cell survival, 929
Cell synchrony, 851
Cerebral blood volume, 663
Cerebral necrosis, 1201
Cervical carcinoma, 75, 839
Chemoradiation, 161
Chemotherapy, 261, 799, 1043, 1179
Childhood, 781
Choroidal melanoma, 1091
Chromosomal aberration assay, 1153
Chromosome aberrations, 861, 1127
Clinical staging, 1037
Colcemid, 851
Collaborative working group, 921
Collimation, 985
Compensator, 693
Complications, 671
Computed tomography, 183
Computer control systems, 1065
Computer-controlled therapy, 971
Concomitant boost, 693
Conformal radiation therapy, 427, 1065
Conformal radiotherapy, 899, 971
Conformal therapy, 685
Conformation, 1233
Continuous, 1107
Cox regression, 1037
Craniospinal, 551
CT stimulator, 979
C3H mammary carcinoma, 1141
Current sheet applicator, 945
Cytokinesis-block micronucleus assay, 1153
Cytoxicity, 117

D

Definitive radiation therapy, 3
Desferrioxamine, 879
Diagnosis, 331
Diagnostic imaging, 685
Disease-free interval, 965
Distant metastases, 1029
Distant relapse, 11
DNA binding proteins, 391
DNA damage, 625
DNA ploidy, 309
DNA repair, 997
Dose, 1073
Dose-rate effect, 83
Dose to lens, 979
Dose volume histogram, 183, 427
Dosimetric model, 447
Downstaging, 169
Dry-eye syndromes, 775
Ductal carcinoma *in situ* (DCIS), 3
Duodenal cancer, 161
Dynamic collimation, 205

E

Early and late radiation-induced damage, 1119
Early glottic cancer, 1059
Early response genes, 229
Early stage, 805
Echo planar MRI, 663
Ectopic bone formation, 63
EGF, 105
EGF-receptors, 105
EIPA, 1161
Elderly patients, 1225
Electron arc therapy, 205
Endocrine function, 781
Endometrial cancer, 831
Endorectal coil magnetic resonance imaging, 293
Endoscopic microsurgery, 1059
Enzymatic assay, 391
Epidermal growth factor, 91, 105
Episcleral wire implant, 1091
Esophageal cancer, 1099, 1225
Essential fatty acids, 1119
Estramustine, 99
Etanidazole, 1153
Evaluation, 909
External beam radiation, 317

F

Ferromagnetic hyperthermia, 929
Ferromagnetic seed, 653
Fibroblast, 625
Fibrosis, 1073
Field placement error, 431
Finite element method, 929
Flow cytometric DNA content analysis, 839
Flow cytometry, 91, 309, 1141
Fludarabine, 363
Fluorescence *in situ* hybridization, 861, 1127
Fluorodeoxyuridine, 601
Fluoropyrimidines, 851
Four orthogonal fields technique, 1083
Fractionation, 477, 575, 609, 619, 721
Fracture healing, 1147
Fructose complex, 643
Function, 347
Functional imaging, 663
Functional MRI, 663

G

^{67}Ga, 447
67-Gallium, 117
γ-Glutamyltranspeptidase, 373
General factors, 1051
Genetic screening, 997
Geriatric oncology, 1225
Gill-Thomas-Cosman frame, 685
Gleason grade, 317
Glioblastoma, 541, 601
Glioma(s), 105, 601, 1201
Glioma cells, 383
Glutathione, 91, 373
Gonadal dose, 1239
Growth factors, 229
GVHD, 821
Gypsum, 693

H

Head and neck, 795
Head and neck cancer(s), 177, 789, 1219
Head and neck neoplasms, 755, 765, 775
Head and neck tumors, 1195
Hemibody irradiation, 825
Heterogeneity corrections, 699
Heterotopic bone, 55
Heterotopic ossification, 63
High dose rate, 75, 473, 831
High dose-rate brachytherapy, 399
High-dose chemotherapy, 151
High-grade glioma, 583
Hip abnormalities, 63
Hip replacement, 55
Histologic damage, 873
HMA, 133, 1161
Hodgkin's disease, 805, 813, 965, 993
HSP-70A, 141
Human carcinoma cells, 99
Human tumors, 141
Hyperfractionation, 551, 609, 1179
Hyperthermia, 399, 591, 945, 1171
Hypopituitarism, 557
Hypoxia, 635
Hypoxic cell radiosensitizer, 1153
Hypoxic fraction, 355

I

^{131}I, 447
Immobilization devices, 211
Injuries to retina, 765
Interstitial brachytherapy, 591
Interstitial hyperthermia, 653
Intracellular acidity, 1161
Intracellular pH, 133
Intraductal carcinoma, 3
Intraoperative radiation, 339
Intraoperative radiation therapy (IORT), 1219
Intraoperative radiotherapy, 1147
Intrathecal administration, 447
Intravaginal treatment, 831
Intrinsic thermal response, 141
Inverse problem, 899
Iodine-125, 1213
Iododeoxyuridine, 583
Ionizing radiation, 391
Ipsilateral breast tumor recurrence, 11
Iridium-192, 1091
Iridium implants, 1073
Irradiation, 347, 873, 1147

J

Jejunal crypt, 873

K

Kaposi's sarcoma, 1207
KU-2285, 1153

L

Late effects, 671
Late radiation damage, 867
Leg contracture, 867
Leukemia, 821
Leukemic and nonleukemic, 141
Linear accelerator, 459, 531, 985
Local control, 309
Local excision, 845
Local tumor control, 1141
Loco-regional control, 1029
Loco-regional relapse, 1029
Low dose rate, 75
Low oxygen breathing, 355
LQ model, 575
Lumpectomy bed, 43
Lumpectomy scar, 43
Lung complications, 821
Lymphatic irradiation, 993
Lymphography, 993

M

Magna field irradiation, 477
Magnetic resonance imaging, 125, 643
Malignant glioma(s), 591, 1179
Malignant lymphoma, 799
Maxillary cancer, 979
MCF-7, 91
Medulloblastoma, 551
Megavoltage computed tomography, 1233
Megavoltage imaging, 1233
Melanoma, 373, 795
Meningeal involvement, 447
Metastatic breast cancer, 151
[^{11}C]Methionine, 1195
Methylxanthine, 411
Microwave, 945
Mimosine, 851
MLC, 707
Moist desquamation, 1141
Molecular biology, 1019
Monkey, 347
Morphology, 347
Mortality, 11
Mouse, 873
Mouse legs, 867
Mouse tumor, 363
mRNA, 141
Multicentric breast cancer, 49
Multileaf collimator, 707, 899, 971, 1065, 1233
Multimodality therapy, 1043
Multivariate analysis, 293
Myelopathy, 609

N

Nasopharyngeal carcinoma, 1029, 1037, 1107, 1111
Neurology, 781
Neutron capture therapy, 643
Neutron radiation therapy, 1065
Neutrons, 105
New method, 715
NonHodgkin's lymphoma, 799
Nonsmall cell lung cancer, 1171
Normal tissue damage, 363, 867
Normal tissue reactions, 625
Normal tissue tolerance, 339
Nuclear extracts, 391

O

Objective function, 929
Oligodendroglioma, 567
Oncogene, 1019
Optic nerve injuries, 755
Optimization, 699, 899
Oropharynx brachytherapy, 1051
Outcome, 567
Ovarian carcinoma, 1083

P

Pancreatic cancer, 161
Pathologic outcome prediction, 293
Pathological Stage IA–IIA, 813
Patient fixation, 685
Patterns of failure, 151
PCNA, 303
Pentoxifylline, 411
Phosphorothioate, 867
Pituitary adenoma, 557
Planning of radiation therapy, 887
PLDR, 383
Pneumonitis, 671
pO_2 histographs, 355
Polarographic electrode, 635
Port filming, 431
Portable software, 921
Portal imaging, 431
Positron emission tomography, 663, 1195
Post- and preoperative hip irradiation, 63
Postoperative, 473
Postoperative radiation, 721
Postradiotherapy prostate biopsies, 303
Predictive assay(s), 625, 789, 1127
Premature chromosome condensation, 1127
Preoperative irradiation, 55
Preoperative radiation, 845
Probability of tumor control, 1111
Prognosis, 35, 309
Prognostic factors, 267, 331, 1029, 1059
Prognostic factors for prostate cancer, 323
Programmed cell death, 619
Proliferative cell nuclear antigen, 303
Prostate, 405, 971
Prostate cancer, 289, 303, 309, 317, 323, 331, 427, 1065
Prostate cancer staging, 293
Prostate carcinoma, 279, 439
Prostate irradiation, 323
Prostate specific antigen, 279, 317, 331, 405
Prostatic specific antigen, 289
Protocol optimization, 721
Pterygium, 721

Q

Quality assurance, 399, 459
Quality of life, 953
Quantitative PCR, 141

R

Radiation, 91, 363, 405, 609, 953, 1043, 1141
Radiation/chemotherapy, 169
Radiation effects, 105
Radiation field shaping, 707
Radiation-induced emesis, 825
Radiation-induced lung damage, 125
Radiation-induced mucositis, 177
Radiation injury, 411
Radiation mediated transcription, 229
Radiation myelopathy, 575
Radiation nephropathy, 677
Radiation sensitizer(s), 583, 601

Radiation therapy, 49, 75, 151, 197, 267, 279, 309, 331, 541, 557, 567, 583, 671, 781, 831, 965, 1059, 1179, 1219, 1225, 1239
Radiation therapy treatment plan optimization, 439
Radiation therapy treatment planning, 439, 663
Radiation tolerance, 997
Radiation treatment, 289
Radical prostatectomy, 317
Radical radiation therapy, 1099
Radioisotopes, 1187
Radiopharmaceuticals, 715
Radioprotector, 867
Radiosensitivity, 83, 625, 1127
Radiosensitization, 99, 851
Radiosensitizer(s), 363, 373, 419, 861
Radiosurgery, 459, 521, 531
Radiotherapy, 177, 197, 221, 261, 431, 551, 635, 795, 799, 805, 813, 909, 959, 997, 1029, 1107, 1171, 1207, 1233
Radiotherapy dosage, 551, 775
Radiotherapy planning, 993
Rat brain tumor, 643
Razoxane, 419
Reccurence, 551
Receptors, 105
Recombinant technology, 1019
Recovery half-time, 383
Recovery kinetics, 383
Rectal cancer, 845
Recurrent cerebral tumor, 1201
Recurrent glioblastoma, 1213
Recurrent rectal cancer, 419
Relapse, 821
Relative biological effectiveness (RBE), 117
Remembered dose, 609
Renovascular hypertension, 677
Retreatment, 575, 609
Risk assessment, 1239

S

Salvage of relapse, 805
Salvage treatment, 3
Sarcoma, 635
Scattered radiation, 985
Selective irradiation, 447
Serotonin, 825
Simultaneous, 35
Skin, 1141
Skin dose, 211
Skin effects, 1119
Skin shrinkage, 867
SLDR, 383
Software engineering, 921
Software tools, 921
Solid cancers, 715
SPECT, 1201
S-phase fraction, 309
Spinal cord, 609
Split-course, 1107
Squamous carcinomas, 105
Squamous cell carcinoma Grade 3, 1107
SR 4233, 879
Statistical study, 1051
Stereotactic, 459
Stereotactic radiation therapy, 531
Stereotactic radiosurgery, 541, 685
Stereotactic radiotherapy, 685
Stereotactic single-dose irradiation, 521
Stereotaxis, 531
Stress response, 229
Sublethal radiation damage repair, 83
Sucralfate mouth washing, 177
Superficial esophageal cancer, 959
Surgery, 1043
Surgery-radiotherapy interval, 17
Surgical clips, 43
Survival analysis, 1037

T

TCD_{50}, 363
Thallium-201, 1201
Therapeutic gain, 643
Therapy, 1187
Thermal modeling, 653, 929
Thermometry artifacts, 399
Thermoradiotherapy, 1171
Thermosensitivity, 1161
Thermosensitizaton, 133
Three-dimensional, 183
Three-dimensional (3-D) CT simulation, 887
Three-dimensional (3-D) treatment planning, 427, 887
Three-dimensional treatment planning, 899, 921, 979, 1065
Thymidylate synthase, 851
Timing factors, 17
Tiron, 879
Tolerance, 609
Total body irradiation, 477, 821, 1133
Total hip arthroplasty, 63
Total proliferative fraction, 309
Total treatment time, 1099
Transcription factors, 391
Transforming growth factor-β, 671
Transurethral surgery, 261
Treatment, 557
Treatment outcome, 789
Treatment planning, 183, 653, 685, 699, 909, 929, 1233
Tumor, 619
Tumor hypoxia, 355
Tumor markers, 323
Tumor oxygenation, 355, 635
Tumor radiosensitivity, 789
Tumor suppressor gene, 1019
Tumor therapy, 105
Tumoral radiobiological, 1051

U

Unilateral nephrectomy, 347
Unperturbed tumor growth, 1111
Ureters, 339

V

Vaginal brachytherapy, 473
Verification, 1233
Vincristine, 1141
Volume, 1073

W

Waiting lists, 221
Waiting time, 1111
Whole abdominal irradiation, 1083
WR-151327, 867